Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib

Journal of Thoracic Oncology

Volumn 10, Issue 2, 2015, Pages 232-236

  Gainor, Justin F ^a   Sherman, Carol A ^b   Willoughby, Kathryn ^b   Logan, Jennifer ^a   Kennedy, Elizabeth ^a   Brastianos, Priscilla K ^a   Chi, Andrew S ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alectinib.; ALK; Anaplastic lymphoma kinase; Leptomeningeal metastases

Indexed keywords

ALECTINIB; AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CERITINIB; CISPLATIN; CORTICOSTEROID; CRIZOTINIB; ETIRACETAM; PEMETREXED; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; BRAIN DISEASE; CANCER PATIENT; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM RELAPSE; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; LEPTOMENINGEAL METASTASIS; LUNG CANCER; MALE; MENINX DISORDER; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOSURGERY; RELAPSE; SEIZURE; SIDE EFFECT; SYSTEMIC DISEASE; TONIC CLONIC SEIZURE; WEAKNESS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; LUNG NEOPLASMS; MENINGEAL NEOPLASMS; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84922281943     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000455     Document Type: Article

References (25)

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566
3. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394
4. Mok T, Kim D, Wu Y, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): Results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32:5s (suppl; abstr 8002
5. Kim D-W, Mehra R, Tan DS, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J Clin Oncol 2014;32:5S (suppl; abstr 8003
6. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013;8:1570-1573
7. Ahn HK, Han B, Lee SJ, et al. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer 2012;76:253-254
8. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase study. Lancet Oncol 2014;15:1119-1128
9. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology 2010;74:1449-1454
10. Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-392
11. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-385
12. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99:283-286
13. Costa D, Shaw A, Ou S, et al. Clinical experience with crizotinib in patients with advanced, ALK-rearranged non-small cell lung cancer and brain metastases in PROFILE 1005 and PROFILE 1007. J Thorac Oncol 2013;8 (suppl; abstr MO07.02
14. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-e445
15. Gandhi L, Drappatz J, Ramaiya NH, Otterson GA. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 2013;8:e3-e5
16. Kim YH, Ozasa H, Nagai H, et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 2013;8:e85-e86
17. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology 1979;29:1369-1375
18. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-57
19. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014;74:1023-1028
20. Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014;134:1484-1494
21. Gettinger S, Bazhenova L, Salgia R, et al. ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data. Ann Oncol 2014;25: iv426-iv470
22. Shaw A, Mehra R, Tan D, et al. Evaluation of ceritinib-treated patients (pts) with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study. Ann Oncol 2014; 25: iv426-iv470
23. Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-smallcell lung cancer. J Thorac Oncol 2014;9:e62-e63
24. United States Food and Drug Administration. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2014/205755lbl.pdf Accessed December 01, 2014
25. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALKresistant mutations. J Med Chem 2014;57:4720-4744